SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma gets USFDA nod for Divalproex Sodium Extended-release Tablets

03 Jun 2014 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Divalproex Sodium Extended-release Tablets USP 250mg and 500mg. Moreover, the product is ready for launch.

Divalproex Sodium Extended-release Tablets USP 250mg and 500mg is the generic equivalent of AbbVie Inc’s Depakote ER Extended-release Tablets, 250mg and 500mg respectively and indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.

The product has a market size of approximately $690 Million for the twelve months ending March 2014 according to IMS. The ANDAs has been approved out of Unit VII (SEZ) formulation facility in Hyderabad.

Following this, the company now has a total of 194 ANDA approvals (168 Final approvals including 7 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1557.75 -18.10 (-1.15%)
01-Jul-2026 10:27 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1874.00
Dr. Reddys Labs. 1346.90
Cipla 1457.70
Zydus Lifesciences 1114.15
Lupin 2407.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: